Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Are age-specific reference ranges for prostate specific antigen population specific?

J M Wolff1, B Brehmer, H Borchers

  • 1Department of Urology, University of Rostock, E-Heydemann Str. 6, 18055 Rostock, Germany.

Anticancer Research
|May 1, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Effectiveness, toxicity and treatment adjustments of lenvatinib plus pembrolizumab in advanced renal cell carcinoma: a multicenter real-world analysis.

ESMO real world data and digital oncology·2026
Same author

Systemic therapy in metastatic renal cell carcinoma (mRCC): an evidence-based recommendation of the German interdisciplinary RCC guidelines group.

World journal of urology·2022
Same author

[Certified residency curriculum for the specialization training in urology from the German Society of Urology according to the 2018 Training Regulations (version of 20. September 2019)].

Der Urologe. Ausg. A·2020
Same author

Comparison of adjustable male slings and artificial urinary sphincter in the treatment of male urinary incontinence: a retrospective analysis of patient selection and postoperative continence status.

World journal of urology·2018
Same author

[Lower urinary tract dysfunction in Guillain-Barre syndrome].

Der Urologe. Ausg. A·2017
Same author

[Not Available].

Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]·2016
Same journal

Corrigendum.

Anticancer research·2026
Same journal

Geographic Variation in Stage at Diagnosis of Skin Cancer in the United States: A National Cancer Database Analysis.

Anticancer research·2026
Same journal

Anti-tumor Effects of Loureirin A Treatment in Colorectal Cancer Cells <i>via</i> Inhibition of AKT Phosphorylation.

Anticancer research·2026
Same journal

Bayesian Analysis to Refine East Asian Subgroup Estimates in the CLEAR Trial (Lenvatinib Plus Pembrolizumab <i>vs</i>. Sunitinib) for Advanced Renal Cell Carcinoma.

Anticancer research·2026
Same journal

Pulsed Electromagnetic Field Increases Doxorubicin-induced Mitotic Slippage in MDA-MB-231 Breast Cancer Cells.

Anticancer research·2026
Same journal

Geographic Disparities in Socioeconomic Factors and Advanced-stage Presentation in Rectosigmoid Cancer: A National Cancer Database Analysis.

Anticancer research·2026
See all related articles

Using age-specific prostate-specific antigen (PSA) ranges did not safely eliminate the need for prostate biopsy in men aged 60-79. Many overlooked prostate cancers had unfavorable histology, highlighting the continued importance of biopsy for accurate diagnosis.

Area of Science:

  • Urology
  • Oncology
  • Diagnostic Medicine

Background:

  • Prostate-specific antigen (PSA) is a key screening marker for prostate cancer.
  • Current screening practices often rely on standard PSA reference ranges.

Purpose of the Study:

  • To evaluate if age-specific PSA reference ranges could safely eliminate the need for prostate biopsy in men aged 60-79.
  • To determine the histological characteristics of prostate cancers potentially missed using age-specific PSA ranges.

Main Methods:

  • Retrospective analysis of men aged 60-79 who underwent radical perineal prostatectomy for prostate cancer.
  • Comparison of cancer detection rates using standard (0-4.0 ng/ml) versus age-specific PSA reference ranges.

Main Results:

Related Experiment Videos

  • Applying age-specific PSA ranges would have overlooked 56 prostate cancers in the study population.
  • Of the overlooked cancers, 54% exhibited unfavorable histology.
  • This contrasts with previous reports where only 5-24% of missed cancers had unfavorable characteristics.

Conclusions:

  • Age-specific PSA reference ranges did not safely eliminate the need for prostate biopsy in this cohort.
  • A significant proportion of potentially missed prostate cancers had unfavorable histology, underscoring biopsy's critical role.